Qianjin Pharmaceutical (600479.SH): Lurasidone hydrochloride tablets obtained drug registration certificate

Zhitong Finance App News, Qianjin Pharmaceutical (600479.SH) issued an announcement. Recently, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. (hereinafter referred to as “Qianjin Xiangjiang Pharmaceutical”), a subsidiary of the company, received the “Drug Registration Certificate” for lurasidone hydrochloride tablets approved and issued by the State Drug Administration. Lurasidone hydrochloride tablets are used to treat schizophrenia. They were first developed by Sunovion Pharmaceuticals Inc., marketed in the US in October 2010, and approved for domestic import in January 2019. Currently, domestic companies that have obtained this drug registration certificate include Jiangsu Haisen Pharmaceutical Group Co., Ltd., Zhengda Tianqing Pharmaceutical Group Co., Ltd., and Zhejiang Haizheng Pharmaceutical Co., Ltd. According to Moentropy Pharmaceutical data, the domestic market sales amount of lurasidone hydrochloride tablets in the first half of 2025 was about 52 million yuan.